ASND US04351P1012

Report

Delayed Nasdaq - 04:00:00 2023-02-03 pm EST
116.10	USD		-1.39%

01/18	Tech Stocks Lead European Equities Modestly Higher in Wednesday Trading	MT
01/17	Pharma Stocks Lead European Equities Higher in Tuesday Trading	MT
01/17	SVB Securities Adjusts Price Target on Ascendis Pharma to $163 From $148, Maintains Outperform Rating	MT

News

Official Publications

Sector news

European ADRs Move Lower in Wednesday Trading

08/24/2022 | 11:04am EST

Stocks mentioned in the article	Change	Last	1st jan.
ADAPTIMMUNE THERAPEUTICS PLC	-4.05%	1.66	18.49%
AKARI THERAPEUTICS, PLC	4.62%	0.51	3.75%
ASCENDIS PHARMA A/S	-1.39%	116.1	-4.94%
BRENT OIL	-2.83%	79.73	-4.54%
CARNIVAL CORPORATION	-1.99%	11.8	46.40%
CELLECTIS S.A.	-20.67%	2.38	19.78%
CRH PLC	0.11%	3942	19.49%
ENI SPA	0.68%	13.844	4.20%
ERYTECH PHARMA S.A.	2.33%	1.14	210.80%
FRESENIUS MEDICAL CARE AG & CO. KGAA	-0.42%	35.61	16.49%
FRESENIUS SE & CO. KGAA	-0.44%	27.11	3.28%
MEREO BIOPHARMA GROUP PLC	-0.86%	0.98	30.67%
MORPHOSYS AG	-1.68%	19	43.83%
NUCANA PLC	3.23%	1.6	142.42%
PRUDENTIAL PLC	0.59%	1354	20.09%
SEQUANS COMMUNICATIONS S.A.	0.62%	3.24	-3.01%
TOTALENERGIES SE	2.12%	56.35	-3.92%
VERONA PHARMA PLC	3.37%	21.19	-21.55%
WTI	0.00%	73.419	-5.67%

All news about ASCENDIS PHARMA A/S

01/18	Tech Stocks Lead European Equities Modestly Higher in Wednesday Trading	MT
01/17	Pharma Stocks Lead European Equities Higher in Tuesday Trading	MT
01/17	SVB Securities Adjusts Price Target on Ascendis Pharma to $163 From $148, Maintains Out..	MT
01/10	BioAtla Sees Dosing of First Patient in Mid-Stage Part 2 Study in Soft Tissue Cancer Th..	MT
01/09	Transcript : Ascendis Pharma A/S Presents at 41st Annual J.P. Morgan Healthca..	CI
01/09	European Equities Begin Week With Sharp Rise	MT
01/09	Ascendis Pharma A/s : INCORPORATION BY REFERENCE - Form 6-K	PU
01/08	Ascendis Pharma Provides Update on Vision 3x3 Strategic Roadmap at 41st Annual J.P. Mor..	AQ
01/04	Online Enrollment Now Open for Physicians Requesting Expanded Access to Ascendis Pharma..	AQ
01/03	Ascendis Pharma A/s : Articles of Association - Form 6-K	PU

More news

Analyst Recommendations on ASCENDIS PHARMA A/S

01/17	SVB Securities Adjusts Price Target on Ascendis Pharma to $163 From $148, Maintains Out..	MT
01/03	Wells Fargo Boosts Price Target on Ascendis Pharma to $177 From $169, Keeps Overweight ..	MT
2022	Morgan Stanley Adjusts Price Target on Ascendis Pharma to $148 From $146, Maintains Ove..	MT

More recommendations

Financials

Sales 2022	45,8 M 49,7 M 49,7 M
Net income 2022	-530 M -575 M -575 M
Net cash 2022	455 M 494 M 494 M
P/E ratio 2022	-11,2x
Yield 2022	-

Capitalization	5 991 M 6 501 M 6 501 M
EV / Sales 2022	121x
EV / Sales 2023	41,1x
Nbr of Employees	639
Free-Float	10,3%

More Financials

Chart ASCENDIS PHARMA A/S

Duration : Period :

Ascendis Pharma A/S Technical Analysis Chart | MarketScreener

Full-screen chart

Technical analysis trends ASCENDIS PHARMA A/S

	Short Term	Mid-Term	Long Term
Trends	Neutral	Bullish	Bullish

Technical analysis

Income Statement Evolution

More Financials

Consensus

Sell Buy
Mean consensus	BUY
Number of Analysts	14
Last Close Price	106,99 €
Average target price	146,94 €
Spread / Average Target	37,3%

Consensus

EPS Revisions

More Estimates Revisions

Managers and Directors

Jan Møller Mikkelsen	President, CEO & Executive Director
Scott Thomas Smith	Chief Financial Officer & Senior Vice President
Albert Cha	Chairman
Birgitte Volck	SVP, Head-Clinical Development & Medical Affairs
Kennett Sprogøe	Senior Vice President, Head-Innovation & Research

More about the company

Sector and Competitors

		1st jan.	Capi. (M$)
	ASCENDIS PHARMA A/S	-4.94%	6 501


REGENERON PHARMACEUTICALS, INC.	4.12%	80 230
VERTEX PHARMACEUTICALS	5.19%	77 978
WUXI APPTEC CO., LTD.	15.80%	41 417
BIONTECH SE	-3.87%	35 092
BEIGENE, LTD.	15.96%	26 559

More Results

ASCENDIS PHARMA A/S

European ADRs Move Lower in Wednesday Trading

Send by mail :